D Tripathy

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi request reprint Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials
    Debu Tripathy
    University of Texas, Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Clin Ther 26:1947-59. 2004
  2. ncbi request reprint Targeted therapies in breast cancer
    Debu Tripathy
    University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Breast J 11:S30-5. 2005
  3. ncbi request reprint Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer
    Debu Tripathy
    University of Texas Southwestern Medical Center, Dallas, USA
    Clin Breast Cancer 5:293-8. 2004
  4. ncbi request reprint Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial
    D Tripathy
    University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Ann Oncol 15:743-50. 2004
  5. ncbi request reprint Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression
    Debu Tripathy
    University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 8852, USA
    J Clin Oncol 22:1063-70. 2004
  6. ncbi request reprint Multidisciplinary care for breast cancer: barriers and solutions
    Debu Tripathy
    President, American Society of Breast Disease and Komen Alliance Breast Cancer Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Breast J 9:60-3. 2003
  7. ncbi request reprint Aromatase inhibitors: rationale and use in breast cancer
    Cynthia Osborne
    University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    Annu Rev Med 56:103-16. 2005
  8. ncbi request reprint Systemic therapy for advanced breast cancer
    Debu Tripathy
    Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    Breast J 10:S26-7. 2004
  9. ncbi request reprint Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials
    Debu Tripathy
    Komen University of Texas Southwestern Breast Cancer Research Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Oncologist 12:375-89. 2007
  10. ncbi request reprint Clinical testing of supplementation therapy in early stage breast cancer: pitfalls and opportunities
    Debu Tripathy
    University of Texas Southwestern Medical Center at Dallas, TX 75390 8852, USA
    Integr Cancer Ther 2:160-2. 2003

Collaborators

Detail Information

Publications38

  1. ncbi request reprint Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials
    Debu Tripathy
    University of Texas, Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Clin Ther 26:1947-59. 2004
    ..Metastatic bone disease is a serious clinical problem in patients with advanced cancer. Bisphosphonates inhibit the activity of osteoclasts and are the treatment of choice for bone metastases...
  2. ncbi request reprint Targeted therapies in breast cancer
    Debu Tripathy
    University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Breast J 11:S30-5. 2005
    ..Fortunately progress in all of these areas is expected with the availability of new technologies and a growing infrastructure for preclinical and clinical testing...
  3. ncbi request reprint Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer
    Debu Tripathy
    University of Texas Southwestern Medical Center, Dallas, USA
    Clin Breast Cancer 5:293-8. 2004
    ..In particular, the benefit from trastuzumab/paclitaxel outweighed the potential risk of CD in patients with MBC. These types of analyses will be critical for trials assessing trastuzumab as adjuvant therapy...
  4. ncbi request reprint Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial
    D Tripathy
    University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Ann Oncol 15:743-50. 2004
    ..We report the first results of a randomized trial assessing a new oral aminobisphosphonate, ibandronate, in patients with bone metastases from breast cancer...
  5. ncbi request reprint Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression
    Debu Tripathy
    University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 8852, USA
    J Clin Oncol 22:1063-70. 2004
    ..We conducted an extension study to this trial to obtain additional safety information and to provide trastuzumab following disease progression...
  6. ncbi request reprint Multidisciplinary care for breast cancer: barriers and solutions
    Debu Tripathy
    President, American Society of Breast Disease and Komen Alliance Breast Cancer Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Breast J 9:60-3. 2003
    ..Finally, these initiatives need to be effectively communicated to the professional and policy-making communities and to the public at large through well-conceived and unbiased educational venues...
  7. ncbi request reprint Aromatase inhibitors: rationale and use in breast cancer
    Cynthia Osborne
    University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    Annu Rev Med 56:103-16. 2005
    ..They are associated with increasing incidence of osteoporosis and bone fractures. Nevertheless, AIs add to our armamentarium for therapy and possible prevention of breast cancer...
  8. ncbi request reprint Systemic therapy for advanced breast cancer
    Debu Tripathy
    Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    Breast J 10:S26-7. 2004
    ..Even though the results of EGFR and VEGF studies have not met with expectations, several preclinical models assessing new combinations of biologic agents with either hormonal therapy or chemotherapy are beginning to show promise...
  9. ncbi request reprint Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials
    Debu Tripathy
    Komen University of Texas Southwestern Breast Cancer Research Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Oncologist 12:375-89. 2007
    ..Significant improvement in time to progression has already been demonstrated in the combination of lapatinib and capecitabine compared with capecitabine monotherapy; for the most part, however, these trials are still in early stages...
  10. ncbi request reprint Clinical testing of supplementation therapy in early stage breast cancer: pitfalls and opportunities
    Debu Tripathy
    University of Texas Southwestern Medical Center at Dallas, TX 75390 8852, USA
    Integr Cancer Ther 2:160-2. 2003
  11. ncbi request reprint Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications
    Cynthia Osborne
    University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390 8852, USA
    Oncologist 9:361-77. 2004
    ....
  12. pmc uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues
    Songdong Meng
    Cancer Immunobiology Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 103:17361-5. 2006
    ..Expression of HER-2 and uPAR in primary tumors predicted gene status in 100 and 92% of patients, respectively...
  13. ncbi request reprint Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil
    Jun Guo
    Harold C Simmons Cancer Center, Division of Hematology Oncology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Acta Pharmacol Sin 27:1375-81. 2006
    ..This study aims to evaluate the potential role of combination therapy with docetaxel, flavopiridol, or 5-FU in modulating chemosensitivity and better understand how they might be used clinically...
  14. ncbi request reprint Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    Charles L Vogel
    University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL, USA
    J Clin Oncol 20:719-26. 2002
    ..To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer...
  15. ncbi request reprint Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer
    Hope Rugo
    University of California, San Francisco Carol Franc Buck Breast Care Center, San Francisco, USA
    Breast Cancer Res Treat 105:17-28. 2007
    ..We studied mechanisms of activity and performed a phase I clinical trial in patients with advanced breast cancer to evaluate BZL101, an aqueous extract from Scutellaria barbata...
  16. ncbi request reprint Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience
    Sue Anne McLachlan
    St Vincent s Hospital, Melbourne, Victoria, Australia
    Clin Drug Investig 26:43-8. 2006
  17. ncbi request reprint Integrative tumor board: metastatic breast cancer
    Amanda Koch
    Block Center for Integrative Cancer Treatment, Evanston, IL 60201, USA
    Integr Cancer Ther 5:373-90. 2006
  18. ncbi request reprint Managing metastatic bone pain: the role of bisphosphonates
    Julie Gralow
    University of Washington School of Medicine, Seattle, Washington 98109, USA
    J Pain Symptom Manage 33:462-72. 2007
    ..Phase III trials are warranted to compare the efficacy of bisphosphonates in treating bone pain and to confirm the effects of intensive dosing regimens...
  19. ncbi request reprint Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer
    Jean Jacques Body
    Institut Jules Bordet, Universite Libre de Bruxelles, 1 rue H├ęger Bordet, 1000 Brussels, Belgium
    Pain 111:306-12. 2004
    ..Oral ibandronate had beneficial effects on bone pain and quality of life and was well tolerated. These results suggest that this treatment is of considerable clinical value as a co-analgesic to patients with painful bone metastases...
  20. ncbi request reprint No evidence for sex differences in the severity and treatment of cancer pain
    Janet M Edrington
    School of Nursing, University of California, San Francisco, California 94143, USA
    J Pain Symptom Manage 28:225-32. 2004
    ..The study findings are important because they suggest that, unlike in acute pain, sex may not influence patients' perceptions of and responses to chronic cancer pain...
  21. ncbi request reprint Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study
    Lorie L Hughes
    Department of Radiation Oncology, WellStar Kennestone Hospital, Marietta, GA 30060, USA
    Cancer 101:969-72. 2004
    ..In the current study, we report the efficacy of pelvic RT with this dose-fractionation scheme in the induction of ovarian ablation...
  22. ncbi request reprint Traditional Chinese medicine in the treatment of breast cancer
    Isaac Cohen
    American Acupuncture Center, Berkeley, CA, USA
    Semin Oncol 29:563-74. 2002
    ..Some of these initiatives in the area of breast cancer prevention and treatment are outlined...
  23. ncbi request reprint Overview: gemcitabine as single-agent therapy for advanced breast cancer
    Debu Tripathy
    Department of Medicine and Cancer Center, Carol Franc Buck Breast Care Center, University of California at San Francisco, 94115 1714, USA
    Clin Breast Cancer 3:8-11. 2002
    ..Larger ongoing studies will help define the utility of gemcitabine in advanced breast cancer..
  24. ncbi request reprint Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer
    Francisco J Esteva
    University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Oncol 21:999-1006. 2003
    ..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent...
  25. ncbi request reprint Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management
    Christine Miaskowski
    Department of Physiological Nursing, School of Nursing, University of California, San Francisco, CA 94143 0610, USA
    J Clin Oncol 22:1713-20. 2004
    ....
  26. ncbi request reprint Gemcitabine in breast cancer: future directions
    Debu Tripathy
    Department of Medicine and Cancer Center, Carol Franc Buck Breast Care Center, University of California at San Francisco, 94115 1714, USA
    Clin Breast Cancer 3:45-8. 2002
    ..Such trials are now either in the planning stages or already under way...
  27. pmc The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management
    Christine Miaskowski
    School of Nursing, University of California, 2 Koret Way Box 0610, San Francisco, CA 94143, USA
    Pain 129:55-63. 2007
    ..The use of responder analysis in analgesic trials may help to identify unique subgroups of patients and lead to the development of more effective psychoeducational interventions...
  28. ncbi request reprint Putting cancer pain management regimens into practice at home
    Karen L Schumacher
    School of Nursing, University of Pennsylvania, Philadelphia, USA
    J Pain Symptom Manage 23:369-82. 2002
    ..Patients and their family caregivers require ongoing assistance with problem-solving to optimize their pain management regimen...
  29. pmc Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain
    Patrice Villars
    School of Nursing, University of California, San Francisco, California 94143, USA
    J Pain Symptom Manage 33:67-77. 2007
    ..Risk factors for analgesic-induced side effects are ATC and ATC+PRN prescription types and higher doses of opioid analgesics...
  30. ncbi request reprint Pain management autobiographies and reluctance to use opioids for cancer pain management
    Karen L Schumacher
    University of Pennsylvania, Philadelphia, USA
    Cancer Nurs 25:125-33. 2002
    ..The study findings suggest that a small subset of patients with cancer pain may need interventions such as individual or family counseling or alternative pain management strategies to augment education about opioids...
  31. ncbi request reprint The usefulness of a daily pain management diary for outpatients with cancer-related pain
    Karen L Schumacher
    School of Nursing, University of Pennsylvania, Philadelphia, PA, USA
    Oncol Nurs Forum 29:1304-13. 2002
    ..To describe the usefulness of daily pain management diaries to outpatients with cancer who participated in a randomized clinical trial of the PRO-SELF Pain Control Program...
  32. ncbi request reprint The PRO-SELF(c): Pain Control Program--an effective approach for cancer pain management
    Claudia M West
    School of Nursing, University of California, San Francisco, CA, USA
    Oncol Nurs Forum 30:65-73. 2003
    ..To describe the PRO-SELF(c): Pain Control Program, an educational approach that provides patients and family caregivers with the knowledge, skills, and nursing support needed to improve pain relief...
  33. ncbi request reprint Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers
    Michelle E Melisko
    University of California, San Francisco, USA
    Clin Breast Cancer 6:45-54. 2005
    ..Also, with increasing patient interest in complementary and alternative medicine (CAM) for cancer, we explored attitudes regarding CAM clinical trials...
  34. ncbi request reprint Qualitative research contribution to a randomized clinical trial
    Karen L Schumacher
    College of Nursing, University of Nebraska Medical Center, Omaha, NE 68132, USA
    Res Nurs Health 28:268-80. 2005
    ..Study results were used to increase the specificity with which the coaching portion of the intervention is described in the intervention protocol...
  35. ncbi request reprint Biologically targeted therapy: as good as advertized?
    Debu Tripathy
    Clin Breast Cancer 4:89. 2003
  36. ncbi request reprint Point-counterpoint: soy intake for breast cancer patients
    Keith I Block
    Block Center for Integrative Cancer Care, 1800 Sherman, Suite 515, Evanston, IL 60201, USA
    Integr Cancer Ther 1:90-100. 2002
  37. ncbi request reprint The PRO-SELF pain control program improves patients' knowledge of cancer pain management
    Jung Eun Kim
    University of California Medical Center, San Francisco, CA, USA
    Oncol Nurs Forum 31:1137-43. 2004
    ..To evaluate the effectiveness of a psychoeducational program (i.e., PRO-SELF Pain Control Program) compared to standard care in increasing patients' knowledge regarding cancer pain management...
  38. doi request reprint Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable
    Julie Gralow
    Department of Medicine, University of Washington, Seattle, WA, USA
    Clin Breast Cancer 8:33-7. 2008
    ..This discussion highlights basic paradigms by which standard taxanes and albumin-bound paclitaxel can be evaluated as possible therapeutic or investigative options, along with nontaxane agents, emerging biologic agents, and combinations...